EP0423266A1 - Method and composition for treatment of periodontal disease - Google Patents
Method and composition for treatment of periodontal diseaseInfo
- Publication number
- EP0423266A1 EP0423266A1 EP90905014A EP90905014A EP0423266A1 EP 0423266 A1 EP0423266 A1 EP 0423266A1 EP 90905014 A EP90905014 A EP 90905014A EP 90905014 A EP90905014 A EP 90905014A EP 0423266 A1 EP0423266 A1 EP 0423266A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- composition
- periodontal disease
- chlorhexidine gluconate
- allantoin
- sodium
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 27
- 208000028169 periodontal disease Diseases 0.000 title claims abstract description 12
- 238000000034 method Methods 0.000 title claims abstract description 9
- 238000011282 treatment Methods 0.000 title abstract description 9
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 claims abstract description 20
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 15
- YZIYKJHYYHPJIB-UUPCJSQJSA-N chlorhexidine gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O.C1=CC(Cl)=CC=C1NC(=N)NC(=N)NCCCCCCNC(=N)NC(=N)NC1=CC=C(Cl)C=C1 YZIYKJHYYHPJIB-UUPCJSQJSA-N 0.000 claims abstract description 13
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims abstract description 12
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims abstract description 12
- 229960003333 chlorhexidine gluconate Drugs 0.000 claims abstract description 11
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 claims abstract description 9
- 229960000458 allantoin Drugs 0.000 claims abstract description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 9
- ABBQHOQBGMUPJH-UHFFFAOYSA-M Sodium salicylate Chemical compound [Na+].OC1=CC=CC=C1C([O-])=O ABBQHOQBGMUPJH-UHFFFAOYSA-M 0.000 claims abstract description 8
- 229960004025 sodium salicylate Drugs 0.000 claims abstract description 7
- 235000011187 glycerol Nutrition 0.000 claims abstract description 6
- 229910000030 sodium bicarbonate Inorganic materials 0.000 claims abstract description 6
- 235000017557 sodium bicarbonate Nutrition 0.000 claims abstract description 6
- 239000008365 aqueous carrier Substances 0.000 claims abstract description 5
- 239000008223 sterile water Substances 0.000 claims abstract description 5
- 239000004615 ingredient Substances 0.000 claims description 6
- 238000004040 coloring Methods 0.000 claims description 5
- 239000000872 buffer Substances 0.000 claims description 4
- 210000004261 periodontium Anatomy 0.000 claims description 4
- 239000003755 preservative agent Substances 0.000 claims description 4
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 2
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims description 2
- 229920000053 polysorbate 80 Polymers 0.000 claims description 2
- 229940068968 polysorbate 80 Drugs 0.000 claims description 2
- 235000019333 sodium laurylsulphate Nutrition 0.000 claims description 2
- 239000000230 xanthan gum Substances 0.000 claims description 2
- 229920001285 xanthan gum Polymers 0.000 claims description 2
- 229940082509 xanthan gum Drugs 0.000 claims description 2
- 235000010493 xanthan gum Nutrition 0.000 claims description 2
- 239000002324 mouth wash Substances 0.000 abstract description 2
- 229940051866 mouthwash Drugs 0.000 abstract description 2
- 208000006735 Periostitis Diseases 0.000 abstract 1
- 210000003460 periosteum Anatomy 0.000 abstract 1
- 229960001407 sodium bicarbonate Drugs 0.000 abstract 1
- 201000001245 periodontitis Diseases 0.000 description 6
- 239000000243 solution Substances 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 4
- 229940068196 placebo Drugs 0.000 description 4
- 239000000902 placebo Substances 0.000 description 4
- 206010061218 Inflammation Diseases 0.000 description 3
- 208000005888 Periodontal Pocket Diseases 0.000 description 3
- 239000002270 dispersing agent Substances 0.000 description 3
- 239000003995 emulsifying agent Substances 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 239000003381 stabilizer Substances 0.000 description 3
- 238000011477 surgical intervention Methods 0.000 description 3
- 239000000080 wetting agent Substances 0.000 description 3
- 206010040943 Skin Ulcer Diseases 0.000 description 2
- 208000008312 Tooth Loss Diseases 0.000 description 2
- 230000000202 analgesic effect Effects 0.000 description 2
- 239000004599 antimicrobial Substances 0.000 description 2
- 230000001680 brushing effect Effects 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 229940098804 peridex Drugs 0.000 description 2
- 230000007406 plaque accumulation Effects 0.000 description 2
- 231100000019 skin ulcer Toxicity 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 206010065687 Bone loss Diseases 0.000 description 1
- OCUCCJIRFHNWBP-IYEMJOQQSA-L Copper gluconate Chemical class [Cu+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O OCUCCJIRFHNWBP-IYEMJOQQSA-L 0.000 description 1
- 208000006558 Dental Calculus Diseases 0.000 description 1
- 241000628997 Flos Species 0.000 description 1
- 206010061274 Malocclusion Diseases 0.000 description 1
- 208000001705 Mouth breathing Diseases 0.000 description 1
- 244000290333 Vanilla fragrans Species 0.000 description 1
- 235000009499 Vanilla fragrans Nutrition 0.000 description 1
- 235000012036 Vanilla tahitensis Nutrition 0.000 description 1
- 230000035508 accumulation Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 229910021538 borax Inorganic materials 0.000 description 1
- 125000000837 carbohydrate group Chemical group 0.000 description 1
- CEZCCHQBSQPRMU-UHFFFAOYSA-L chembl174821 Chemical compound [Na+].[Na+].COC1=CC(S([O-])(=O)=O)=C(C)C=C1N=NC1=C(O)C=CC2=CC(S([O-])(=O)=O)=CC=C12 CEZCCHQBSQPRMU-UHFFFAOYSA-L 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 230000003239 periodontal effect Effects 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- PUZPDOWCWNUUKD-UHFFFAOYSA-M sodium fluoride Chemical compound [F-].[Na+] PUZPDOWCWNUUKD-UHFFFAOYSA-M 0.000 description 1
- 235000010339 sodium tetraborate Nutrition 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 229940034610 toothpaste Drugs 0.000 description 1
- 239000000606 toothpaste Substances 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- BSVBQGMMJUBVOD-UHFFFAOYSA-N trisodium borate Chemical compound [Na+].[Na+].[Na+].[O-]B([O-])[O-] BSVBQGMMJUBVOD-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q11/00—Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/36—Carboxylic acids; Salts or anhydrides thereof
- A61K8/368—Carboxylic acids; Salts or anhydrides thereof with carboxyl groups directly bound to carbon atoms of aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/43—Guanidines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/494—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom
- A61K8/4946—Imidazoles or their condensed derivatives, e.g. benzimidazoles
Definitions
- the present invention relates to a method and composition for treatment of periodontal disease and, more particularly, to a composition suitable for topical application to prevent and treat periodontitis.
- Periodontal disease is the major cause of tooth loss in adults.
- the periodontium is subject to inflammation for many reasons, primary among them being the accumulation of plaque deposits under and above the gumline.
- These calcareous deposits of organic and mineral matter consist of microbial colonies growing in carbohydrate residues (from food) , attach themselves to tooth surfaces and can, over time, calcify into tartar. This hard, mineralized substance adheres tenaciously to the teeth and, when under the gumline, causes inflammation of the periodontium.
- Other causes of periodontitis can include malocclusion, food impaction and mouth breathing.
- Periodontitis outside of taking preventive measures to keep it from developing in the first place, was surgery.
- the accepted surgical procedure involves removing the inflamed gum tissue, which is expensive and requires a long and painful recovery.
- a composition suitable for treating periodontitis comprises an aqueous solution of an antimicrobial agent with bacteriacidal activity, an agent with therapeutic action against skin ulcers, an analgesic, a stain remover and, if desired, suitable wetting agents, emulsifiers, dispersants, buffers stabilizers, preservatives, flavoring and coloring.
- the various components of the composition of the present invention are present in an aqueous carrier of sterile distilled water, glycerine and ethanol.
- the glycerine provides the composition with the desired feel and texture and the ethanol acts as an antiseptic.
- chlorhexidine gluconate (0.12% solution), C 3 H 5 Cl 2 N 10 O 14 (Merck Index 2057) , as an antimicrobial agent with bacteriacidal action, (2) allantoin, or (2,5-dioxo-4- imidazolidinyl)urea (Merck Index 242) as an agent that exhibits therapeutic action against skin ulcers, (3) sodium salicylate, or 2-hydroxybenzoic acid monosodium salt (Merck Index 8515) , as an analgesic, and (4) sodium bicarbonate (Merck Index 8414) as a stain remover, along with wetting agents, preservatives, emulsifiers, dispersants, buffers stabilizers, flavoring and coloring, as desired. (All references herein to the Merck Index refer to the 1983 edition.)
- the above ingredients are provided in the following proportions:
- Ethanol (MI 212) 7.50% Polysorbate 80 (as an emulsifier and dispersant; MI 7455) 4.20% Chlorhexidine gluconate (0.12% sol.) (MI 2057) 3.50% Sodium bicarbonate (as a stain remover; MI 8414) 0.50% Sodium lauryl sulfate (as a wetting agent; MI 8474) 0.50%
- MI 8413 0.10% Xanthan gum (as a stabilizer and e ulsifier; MI 9868) 0.10%
- the above composition is prepared by first measuring an appropriate quantity of sterile distilled water; for example, lOOOcc of the composition is to be prepared, 101 . lc . of water are used. The remaining ingredients are added in the order listed in Table 1, with each ingredient being thoroughly mixed by gently stirring the composition before the next ingredient is added.
- a clinical test involving 30 people was performed using a composition similar to that set out above, except for using 72.77% sterile water, 8.00% ethanol, 1.50% chlorhexidine gluconate (0.12% solution) and 0.138% allantoin.
- the subjects were chosen because all exhibited, periodontal pockets up to 8mm or 9mm deep.
- Prior to beginning the treatment regimen all 30 subjects agreed not to brush or floss their teeth for one week.
- 15 of the subjects rinsed their mouths three times a day with 1.0 cc of the above composition 30 seconds before brushing and 15 rinsed their mouths three times a day with an equal amount of a colored sugar-water placebo 30 seconds before brushing.
- the subjects did not know whether they were using the inventive composition or the placebo.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Emergency Medicine (AREA)
- Cosmetics (AREA)
Abstract
Une composition de traitement de maladie périodontique comprend un support aqueux d'eau stérile, de glycérine et d'éthanol, dans lequel sont présents gluconate de chlorhexidine, allantoïne, salicylate de sodium et bicarbonate de sodium. Un procédé de traitement préféré consiste en l'application locale au périoste alvéolaire de l'homme dans un bain de bouche.A periodontal disease treatment composition comprises an aqueous carrier of sterile water, glycerin and ethanol, in which are present chlorhexidine gluconate, allantoin, sodium salicylate and sodium bicarbonate. A preferred treatment method consists of local application to the human alveolar periosteum in a mouthwash.
Description
METHOD AND COMPOSITION FOR TREATMENT OF PERIODONTAL DISEASE
BACKGROUND OF THE INVENTION
Field of the Invention
The present invention relates to a method and composition for treatment of periodontal disease and, more particularly, to a composition suitable for topical application to prevent and treat periodontitis.
Description of the Prior Art
Periodontal disease is the major cause of tooth loss in adults. The periodontium is subject to inflammation for many reasons, primary among them being the accumulation of plaque deposits under and above the gumline. These calcareous deposits of organic and mineral matter, which consist of microbial colonies growing in carbohydrate residues (from food) , attach themselves to tooth surfaces and can, over time, calcify into tartar. This hard, mineralized substance adheres tenaciously to the teeth and, when under the gumline, causes inflammation of the periodontium. Other causes of periodontitis can include malocclusion, food impaction and mouth breathing.
Periodontitis can cause the gumline to retract due to supporting bone loss and the gums to bleed, and eventually, if not treated, can result in tooth loss. Until now, the only known treatment for periodontitis, outside of taking preventive measures to keep it from developing in the first place, was surgery. The accepted surgical procedure involves removing the inflamed gum
tissue, which is expensive and requires a long and painful recovery.
There have been various attempts at treating periodontal disease without such surgical intervention. The best such attempt to date resides in an oral rinse sold by Procter & Gamble under the name Peridex®. The chemistry of this product is described in the 1988 Phvsicans' Desk Reference at pages 1648-49. Unfortunately, Peridex® rinse has not proved as efficacious against periodontal disease as might be desired and exhibits unwanted side effects, such as staining of tooth surfaces.
The following patents also disclose oral treatment agents, but none is believed to represent a substitute for surgical intervention as a treatment for periodontal disease:
Re.31,397 4,213,961
2,684,924 4,332,791
3,887,712 4,339,430
3,925,543 4,454,110
3,937,807 4,486,404
3,957,967 4,569,837
4,051,234 4,601,900
4,067,962 4,661,342 4,198,392
Of interest with regard to the present invention are U.S. Patent 4,486,404 which, in Example 5, discloses a toothpaste containing chlorhexidine gluconate and allantoin, U.S. Patents 3,937,807 and 4,051,234, which disclose mouthwashes with gluconates and anti-stain agents, and U.S. Patent 4,569,837, which discloses the use of chlorhexidine gluconate and aspirin to treat periodontal disease.
SUMMARY OF THE INVENTION It is an object of the present invention to provide a composition and method for treating Periodontitis I without costly and painful surgical intervention.
In accordance with one aspect of the invention, a composition suitable for treating periodontitis comprises an aqueous solution of an antimicrobial agent with bacteriacidal activity, an agent with therapeutic action against skin ulcers, an analgesic, a stain remover and, if desired, suitable wetting agents, emulsifiers, dispersants, buffers stabilizers, preservatives, flavoring and coloring.
In accordance with another aspect of the invention, the composition is used in a treatment method which comprises the steps of topically applying the composition to inflamed periodontium.
DESCRIPTION OF PREFERRED EMBODIMENTS In a preferred embodiment of the invention the various components of the composition of the present invention are present in an aqueous carrier of sterile distilled water, glycerine and ethanol. The glycerine provides the composition with the desired feel and texture and the ethanol acts as an antiseptic.
To this water-glycerine-ethanol carrier is added (1) chlorhexidine gluconate (0.12% solution), C3H5Cl2N10O14 (Merck Index 2057) , as an antimicrobial agent with bacteriacidal action, (2) allantoin, or (2,5-dioxo-4- imidazolidinyl)urea (Merck Index 242) as an agent that
exhibits therapeutic action against skin ulcers, (3) sodium salicylate, or 2-hydroxybenzoic acid monosodium salt (Merck Index 8515) , as an analgesic, and (4) sodium bicarbonate (Merck Index 8414) as a stain remover, along with wetting agents, preservatives, emulsifiers, dispersants, buffers stabilizers, flavoring and coloring, as desired. (All references herein to the Merck Index refer to the 1983 edition.)
In particularly preferred embodiment, the above ingredients are provided in the following proportions:
TABLE 1
Sterile Water 70.77%
Glycerine (MI 4347) 11.15%
Ethanol (MI 212) 7.50% Polysorbate 80 (as an emulsifier and dispersant; MI 7455) 4.20% Chlorhexidine gluconate (0.12% sol.) (MI 2057) 3.50% Sodium bicarbonate (as a stain remover; MI 8414) 0.50% Sodium lauryl sulfate (as a wetting agent; MI 8474) 0.50%
Vanilla (as flavoring; MI 9732) 0.60%
Saccharine (as flavoring; MI 8170) 0.20%
Sodium salicylate (MI 8515) 0.15%
Allantoin (MI 242) 0.638% Sodium benzoate (as a preservative;
MI 8413) 0.10%
Xanthan gum (as a stabilizer and e ulsifier; MI 9868) 0.10%
Sodium borate (as a buffer; MI 8421) 0.085%
F.D.& C. Blue (as coloring) 0.005%
F.D.& C. Red 40 (as coloring) 0.002%
[Notes to Table 1 - (1) All proportions of the above ingredients are v/v; (2) "MI" refers to the Merck Index]
The above composition is prepared by first measuring an appropriate quantity of sterile distilled water; for example, lOOOcc of the composition is to be prepared, 101 . lc . of water are used. The remaining ingredients are added in the order listed in Table 1, with each ingredient being thoroughly mixed by gently stirring the composition before the next ingredient is added.
A clinical test involving 30 people was performed using a composition similar to that set out above, except for using 72.77% sterile water, 8.00% ethanol, 1.50% chlorhexidine gluconate (0.12% solution) and 0.138% allantoin. The subjects were chosen because all exhibited, periodontal pockets up to 8mm or 9mm deep. Prior to beginning the treatment regimen, all 30 subjects agreed not to brush or floss their teeth for one week. Then, 15 of the subjects rinsed their mouths three times a day with 1.0 cc of the above composition 30 seconds before brushing and 15 rinsed their mouths three times a day with an equal amount of a colored sugar-water placebo 30 seconds before brushing. The subjects did not know whether they were using the inventive composition or the placebo.
Once a week the teeth of each subject were checked for the presence of plaque using a commercially available plaque- disclosing solution, Superdent® disclosing solution
concentrate, made by Rugby Laboratories, Inc., of Rockville Centre, Long Island, NY 11570. All subjects using the inventive composition showed little or no plaque accumulation, while there was such plaque accumulation on the teeth of the subjects using the placebo.
The test procedures were continued for 12 weeks, and the subjects' conditions were measured in accordance with the Simplified Oral Hygiene Index (OHI-S) described in Orban's Periodontics (3rd Ed. 1968), The C.V. Mosby Co., St. Louis, MO, at page 134. It was found that the average OHI-S for the subjects on the placebo went from 8mm to 9mm periodontal pocket depth to 6mm to 8mm pocket depth during the 12 week test, while that for the subjects using the inventive composition improved from 8mm" to 9mm periodontal pocket depth to 2mm or 3mm pocket depth, which is considered within normal range.
It is expected that repeated use of the inventive solution will reduce inflammation, stop bleeding and keratenize damaged periodontal tissue.
Of course, variations of the above preferred embodiment are possible within the scope of the present invention, such as varying the proportions of the chlorhexidine gluconate, allantoin and sodium salicylate within ranges that provide efficacious results. It is intended by the claims appended below to include all such variations within the present invention.
Claims
1. A composition for treating periodontal disease comprising an aqueous carrier having therein chlorhexidine gluconate, allantoin and sodium salicylate.
2. A composition according to claim 1, further comprising a stain remover.
3. A composition according to claim 2, wherein said stain remover is sodium bicarbonate.
4. A composition according to claim 1, wherein said chlorhexidine gluconate is present as a 0.12% solution and said aqueous carrier consists essentially of sterile water, glycerine and ethanol.
5. A composition for treating periodontal disease consisting essentially of the following ingredients in the following amounts according to volume:
Sterile Water 70.77%
Glycerine 11.15%
Ethanol 7.50%
Polysorbate 80 4.20% Chlorhexidine gluconate (0.12% sol.) 3.50%
Sodium bicarbonate 0.50%
Sodium lauryl sulfate 0.50%
Sodium salicylate 0.15%
Allantoin 0.638% Xanthan gum 0.10%
Preservatives, buffers, flavoring and coloring 0.992%
6. A method for treating periodontal disease comprising the steps of: providing a composition including an aqueous carrier having therein chlorhexidine gluconate, allantoin and sodium salicylate; and applying said composition topically to a human periodontium.
7. A method according to claim 5, wherein the composition further includes a stain remover.
8. A method according to claim 6, wherein the stain remover is sodium bicarbonate.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US31727189A | 1989-02-28 | 1989-02-28 | |
| US317271 | 1989-02-28 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EP0423266A1 true EP0423266A1 (en) | 1991-04-24 |
| EP0423266A4 EP0423266A4 (en) | 1991-09-25 |
Family
ID=23232900
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP19900905014 Withdrawn EP0423266A4 (en) | 1989-02-28 | 1990-02-28 | Method and composition for treatment of periodontal disease |
Country Status (4)
| Country | Link |
|---|---|
| EP (1) | EP0423266A4 (en) |
| AU (1) | AU5287090A (en) |
| CA (1) | CA2028136A1 (en) |
| WO (1) | WO1990009779A1 (en) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1257345B (en) | 1992-06-02 | 1996-01-15 | HIGHLY EFFECTIVE SCLEROSANT SOLUTION, WHICH DOES NOT PRODUCE IATROGEN INJURY AND PROCEDURE TO OBTAIN THIS SOLUTION. | |
| US6486214B1 (en) | 1997-09-10 | 2002-11-26 | Rutgers, The State University Of New Jersey | Polyanhydride linkers for production of drug polymers and drug polymer compositions produced thereby |
| US6468519B1 (en) | 1997-09-10 | 2002-10-22 | Rutgers, The State University Of New Jersey | Polyanhydrides with biologically active degradation products |
| US6864274B2 (en) | 1999-07-23 | 2005-03-08 | Alwyn Company, Inc. | Allantoin-containing skin cream |
| US6281236B1 (en) | 1999-07-23 | 2001-08-28 | Alwyn Company, Inc. | Oil-in-water emulsion with improved stability |
| US20020054895A1 (en) | 1999-07-23 | 2002-05-09 | Alwyn Company, Inc. | Allantoin-containing skin cream |
| US6329413B1 (en) | 1999-07-23 | 2001-12-11 | Alwyn Company, Inc. | Allantoin-containing skin cream |
| US6531500B2 (en) | 1999-07-23 | 2003-03-11 | Alwyn Company, Inc. | Methods for treatment of inflammatory diseases |
| US6673826B2 (en) | 1999-07-23 | 2004-01-06 | Alwyn Company, Inc. | Methods for treatment of inflammatory diseases |
| US6896897B2 (en) | 1999-07-23 | 2005-05-24 | Alwyn Company, Inc. | Flexible applicator for applying oil-in-water emulsion with improved stability |
| US20040038948A1 (en) | 1999-12-07 | 2004-02-26 | Uhrich Kathryn E. | Therapeutic compositions and methods |
| DE60043075D1 (en) * | 1999-12-07 | 2009-11-12 | Univ Rutgers | THERAPEUTIC COMPOSITIONS AND METHOD FOR TREATING PERIODONTITIS WITH INFLAMMATORY MEDIUM-SUBSTANCES |
| US6685928B2 (en) | 1999-12-07 | 2004-02-03 | Rutgers, The State University Of New Jersey | Therapeutic compositions and methods |
| EP2338465A1 (en) | 2005-11-09 | 2011-06-29 | Klox Technologies Inc. | Teeth whitening compositions and methods |
| EP2102144A4 (en) | 2006-09-13 | 2011-03-23 | Univ Rutgers | ACTIVE AGENTS AND OLIGOMERS AND POLYMERS THEREOF |
| US20100266989A1 (en) | 2006-11-09 | 2010-10-21 | Klox Technologies Inc. | Teeth whitening compositions and methods |
| LT2352488T (en) | 2008-11-07 | 2017-05-25 | Klox Technologies Inc. | Oxidative photoactivated skin rejuvenation composition comprising hyaluronic acid, glucosamine, or allantoin |
| SMT201700575T1 (en) | 2009-07-17 | 2018-01-11 | Klox Tech Inc | Antibacterial oral composition |
| US20140135372A1 (en) | 2010-02-02 | 2014-05-15 | Elliott Farber | Compositions and methods of treatment of inflammatory skin conditions using allantoin |
| US11116841B2 (en) | 2012-04-20 | 2021-09-14 | Klox Technologies Inc. | Biophotonic compositions, kits and methods |
| US20130281913A1 (en) | 2012-04-20 | 2013-10-24 | Klox Technologies Inc. | Biophotonic compositions and methods for providing biophotonic treatment |
| US9144579B2 (en) | 2012-08-17 | 2015-09-29 | Rutgers, The State University Of New Jersey | Polyesters and methods of use thereof |
| CA2884349C (en) | 2012-09-14 | 2019-03-26 | Valeant Pharmaceuticals International, Inc. | Compositions and methods for teeth whitening |
| US20140120057A1 (en) | 2012-10-25 | 2014-05-01 | Rutgers, The State University Of New Jersey | Polymers and methods thereof for wound healing |
| US20140276354A1 (en) | 2013-03-14 | 2014-09-18 | Klox Technologies Inc. | Biophotonic materials and uses thereof |
| US9387250B2 (en) | 2013-03-15 | 2016-07-12 | Rutgers, The State University Of New Jersey | Therapeutic compositions for bone repair |
| WO2014194055A1 (en) | 2013-05-29 | 2014-12-04 | Rutgers, The State University Of New Jersey | Antioxidant-based poly(anhydride-esters) |
| WO2015000058A1 (en) | 2013-07-03 | 2015-01-08 | Klox Technologies Inc. | Biophotonic compositions comprising a chromophore and a gelling agent for treating wounds |
| CN103893026B (en) * | 2014-03-31 | 2018-04-06 | 陈光健 | It is a kind of to be used for oral cleaning and the mouthwash of health care |
| AU2015240385B2 (en) | 2014-04-01 | 2019-02-28 | Klox Technologies Inc. | Tissue filler compositions and methods of use |
| WO2015191742A1 (en) | 2014-06-13 | 2015-12-17 | Rutgers, The State University Of New Jersey | Process and intermediates for preparing poly(anhydride-esters) |
| JP2018500468A (en) | 2014-10-31 | 2018-01-11 | クロックス テクノロジーズ インコーポレイテッドＫｌｏｘ Ｔｅｃｈｎｏｌｏｇｉｅｓ Ｉｎｃ． | Photoactive fiber and textile media |
| JP6930918B6 (en) | 2015-04-10 | 2021-12-15 | ラトガーズ， ザ ステイト ユニバーシティ オブ ニュー ジャージー | Kojic acid polymer |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2529271C3 (en) * | 1975-07-01 | 1979-05-03 | Erich 2400 Luebeck Hofacker | Use of chlorhexidine and allantoin |
| US4370314A (en) * | 1975-12-08 | 1983-01-25 | Colgate-Palmolive Company | Oral composition containing antibacterial agent |
| IT1150603B (en) * | 1982-01-26 | 1986-12-17 | Ugo Baldacci | COMPOSITION FOR CLEANING AND DENTAL HYGIENE |
| US4454110A (en) * | 1982-05-24 | 1984-06-12 | Forsyth Dental Infirmary For Children | Self-gelling liquid composition for topical application in the oral cavity |
| US4512968A (en) * | 1982-11-30 | 1985-04-23 | Lion Corporation | Oral compositions |
| JPS59222406A (en) * | 1983-06-01 | 1984-12-14 | Teijin Ltd | Pharmaceutical preparation for remedying periodontosis and its preparation |
| WO1987005501A1 (en) * | 1986-03-17 | 1987-09-24 | Oral Research Laboratories, Inc. | Treatment of dental surfaces with plaque retardants |
-
1990
- 1990-02-28 WO PCT/US1990/001041 patent/WO1990009779A1/en not_active Ceased
- 1990-02-28 EP EP19900905014 patent/EP0423266A4/en not_active Withdrawn
- 1990-02-28 CA CA 2028136 patent/CA2028136A1/en not_active Abandoned
- 1990-02-28 AU AU52870/90A patent/AU5287090A/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| AU5287090A (en) | 1990-09-26 |
| EP0423266A4 (en) | 1991-09-25 |
| WO1990009779A1 (en) | 1990-09-07 |
| CA2028136A1 (en) | 1990-09-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0423266A1 (en) | Method and composition for treatment of periodontal disease | |
| Mandel | Antimicrobial mouthrinses: overview and update | |
| Ernst et al. | The effectiveness and side effects of 0.1% and 0.2% chlorhexidine mouthrinses: a clinical study. | |
| Balagopal et al. | Chlorhexidine: the gold standard antiplaque agent | |
| EP0169888B1 (en) | Dental rinse | |
| US4097604A (en) | Method of treating and controlling gingivitis | |
| US7115252B2 (en) | Therapeutic compositions and methods of use thereof | |
| US5236699A (en) | Antiplaque mouth rinse | |
| US3651208A (en) | Dentifrice for periodontia purposes | |
| US4215144A (en) | Method of treating and controlling gingivitis | |
| Mandel | Calculus update: prevalence, pathogenicity and prevention | |
| US4839158A (en) | Process and composition for oral hygiene | |
| US6589513B2 (en) | Oral hygiene formulation and method of use | |
| US4214006A (en) | Mouthwash and method for preventing and removing dental plaque | |
| JP2981772B2 (en) | Dental hygiene composition for reducing periodontal disease | |
| Holbeche et al. | A clinical trial of the efficacy of a cetylpyridinium chloride‐based mouth wash*: 1. Effect on plaque accumulation and gingival condition | |
| US5403579A (en) | Process and composition for oral hygiene | |
| RU2119328C1 (en) | Toothpaste | |
| US6497858B1 (en) | Method of remineralizing teeth | |
| JP2548265B2 (en) | Oral hygiene medicine | |
| US6440395B1 (en) | Antiplaque mouth rinse | |
| Bokor | The effect of hexetidine spray on dental plaque following periodontal surgery | |
| CA2481004A1 (en) | Novel anti-bacterial compositions | |
| Asrorovna et al. | Clinical And Morphological Assessment Of The Effectiveness Of Application Of Anti-Inflammatory Toothpasts In The Complex Treatment Of Periodontal Diseases In Patients With Glucose Exchange | |
| Yengopal | Essential oils: some lesser known uses and properties for improved oral health |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| 17P | Request for examination filed |
Effective date: 19901026 |
|
| AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB IT LI LU NL SE |
|
| A4 | Supplementary search report drawn up and despatched |
Effective date: 19910808 |
|
| AK | Designated contracting states |
Kind code of ref document: A4 Designated state(s): AT BE CH DE DK ES FR GB IT LI LU NL SE |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN |
|
| 18W | Application withdrawn |
Withdrawal date: 19920331 |